Track topics on Twitter Track topics that are important to you
Xencor acknowledged today that the FDA has placed the company’s Phase I trial of its CD123 x CD3 bispecific antibody XmAb®14045 on a partial clinical hold following the deaths of two patients linked to the blood cancer candidate. Xencor said one patient experienced cytokine release syndrome (CRS) after their first dose, “the treatment of which […] The post After 2 Patient Deaths, FDA Im...
@Genentech did you know we have a triple Cytokine immune therapy in development? One includes IL-15. #CallMeLetsTalk Genentech to Develop Xencor IL-15 Cytokines in Immuno-Oncology Partnership https://www.genengnews.com/news/genentech-to-develop-xencor-il
@Genentech did you know we have a triple Cytokine immune therapy in development? One includes IL-15. #CallMeLetsTalk Genentech to Develop Xencor IL-15 Cytokines in Immuno-Oncology Partnership https://www.genengnews.com/news/genentech-to-develop-xencor-il-15-cytokines-in-immuno-oncology-partnership/ … via
Deals b/w checkpoint inhibitor players & cytokine players. Synergy in the space! pic.twitter.com/EKnj1BXUmh
1. IL-2 is a central cytokine that enhances the immune response, with considerable potential for the treatment of cancer. 2. A mimic of IL-2 binds its receptor more tightly and more potently than the natural cytokine, without adverse effects, in mouse models of melanoma and colon cancer. Evidence Rating Level: 2 [Good] Study Rundown: As […] Source: 2 Minute Medicine
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Genentech pays Xencor $120M for rights to IL-15 cancer pipeline .Genentech has paid $120 million upfront to secure global rights to IL-15 cytokine therapeutics in preclinical development at … Continue reading →
Acute gouty arthritis currently is the most common form of inflammatory arthritis in developed countries. Treatment is still suboptimal. Dosage of urate-lowering therapy is often too low to reach target urate ...
Roche partners with Xencor to develop IL-15 cytokine therapeutics for cancer https://www.firstwordpharma.com/node/1623241 $RHHBY $XNCR
Genentech, a member of the Roche group, will partner with Xencor to develop and commercialize its novel IL-15 cytokine therapeutics—including its most advanced preclinical cytokine program, the cancer candidate XmAb®24306, the companies said today, through a collaboration that could generate more than $280 million for Xencor. Xencor could see even more money if the companies […] The post ...
Can Fite’s drugs robustly inhibit the release of inflammatory mediators that induce Cytokine Release Syndrome (CRS), a potentially fatal side effect of CAR-T and other immune-oncology therapies Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a
The U.S. FDA grants an orphan drug designation to BBT-877 in IPF The first-in-human clinical study is set to begin next month SEONGNAM, South Korea, Jan. 16, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea and a tenant company of JLABS@TMC in Houston, Texas, announced that the U.S. Food and Drug Administration (FDA)...
The new instrument platform and highly validated CorPlex assays promise to revolutionize oncology research and drug development. The progress made since the early access program was initiated in The post Quanterix announces full launch of 10-plex Simoa Corplex Cytokine panel appeared first on Compelo Medical Devices.
$NK Launches Merkel Cell Carcinoma PII Trial Deploying Novel Triple Combo of haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy https://www.businesswire.com/news/home/20190109005307/en/NantKwest-Announces-
$NK Launches Merkel Cell Carcinoma PII Trial Deploying Novel Triple Combo of haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy https://www.businesswire.com/news/home/20190109005307/en/NantKwest-Announces-Launch-Merkel-Cell-Carcinoma-Phase …
Initial data shows HPN424 serum exposure supports weekly dosing Changes in blood-derived tumor cell and serum biomarkers consistent with T cell activation HPN424 dose escalation proceeding to identify Phase 2 therapeutic dose Harpoon Therapeutics, Inc. ("Harpoon"), a clinical-stage immunotherapy company developing a n...
Very interesting work by @MarcoLDavila et al https://www.nature.com/articles/d41586-018-07581-w … Catecholamines fuels a cytokine storm during #immunotherapy; Old hypertension drug metyrosine could treat CRS https://www.nature.com/articles/s41586-018
Very interesting work by @MarcoLDavila et al https://www.nature.com/articles/d41586-018-07581-w … Catecholamines fuels a cytokine storm during #immunotherapy; Old hypertension drug metyrosine could treat CRS https://www.nature.com/articles/s41586-018-0774-y …
A-319 and A-329 immunotherapies may prove beneficial in patients with B cell malignancies with less frequent dosing and lower cytokine inductions December 3rd, 2018, Shanghai, Generon BioMed Holding Ltd (Generon), announced today at the American Society of Hematology (ASH) Annual Meeting the pre-clinical study results of two novel immunotherapies, ...
In this webinar on December 5, attendees will learn what xMAP® Technology is, how it is used, and the common challenges and solutions with multiplexing technology, in addition to the associated benefits to the drug discovery workflow. YORBA LINDA, Calif. (PRWEB) December 04, 2018 The mouse is a critical, increasingly used model system in biomedical research and preclinical drug discovery. Wh...
Novel Trisprcific CD19.t-haNKTM Natural Killer Cell Therapy Engineered for Enhanced Tumor Homing for B Cell Lymphoma NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases ...
$CCXI Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at #AACR18 https://globenewswire.com/news-release/2018/11/29/1659404/0/en/ChemoCentryx-s-Novel-Small-Molecule-Antagonists-of-Checkpoint-Inhibitors-and-
$CCXI Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at #AACR18 https://globenewswire.com/news-release/2018/11/29/1659404/0/en/ChemoCentryx-s-Novel-Small-Molecule-Antagonists-of-Checkpoint-Inhibitors-and-Chemokine-Receptors-to-be-Presented-at-the-American-Association-for-Cancer-Research-AACR-Tumor-Immunolo.html
SummaryChemoCentryx Inc ChemoCentryx is a biopharmaceutical company that discovers, develops and commercializes orallyadministered therapeutics for the treatment of cancer, autoimmune diseases, and inflammatory disorders. The company's lead drug candidate include Avacopan, an orallyadministered complement inhibitor of the complement C5a receptor C5aR, for the treatment of antineutrophil cytoplasmi...
CXC Chemokine Receptor Type 1 CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1 Pipeline Review, H2 2018SummaryAccording to the recently published report 'CXC Chemokine Receptor Type 1 Pipeline Review, H2 2018'; CXC Chemokine Receptor Type 1 CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1 pipeline Target constitu...
The first-in-human study will be initiated early next year Orphan Drug Designation application was filed for IPF SEONGNAM, South Korea, Nov. 18, 2018 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea and a tenant company of JLABS@TMC in Houston, Texas, announced that the company filed an Investigational New Drug (IND) appl...
Extracellular matrix proteins tenascin-C (TNC) and periostin, which were identified as T-helper cell type 2 cytokine-induced genes in human bronchial epithelial cells, accumulate in the airway basement membran...
Chorioamnionitis is a risk factor for future asthma development. Animal models of chorioamnionitis demonstrate increased TH17-to-Treg ratios associated with proinflammatory cytokine elevations. The association of...
Brooklyn ImmunoTherapeutics Announces Presentation of Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer
Statistically significant increase in tumor-infiltrating lymphocytes reported PD-L1 upregulation in early stage breast cancer patients Well-tolerated with no Grade III/IV treatment-emergent toxicities reported Brooklyn ImmunoTherapeutics, a